Levetiracetam Micro Labs

Levetiracetam, the active ingredient in Levetiracetam Micro Labs, is an anticonvulsant (pyrrolidine derivative) presented as an oral tablet for oral administration. It is indicated for the treatment of partial‑onset seizures, generalized tonic‑clonic seizures, and myoclonic seizures in patients diagnosed with epilepsy, helping to reduce seizure frequency and improve neurological stability.

GNH USA supplies Levetiracetam Micro Labs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Levetiracetam is an anticonvulsant used to control seizure activity across several epilepsy syndromes.

- Partial-onset seizures: reduces frequency of focal seizures and improves seizure control. - Generalized tonic-clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. - Myoclonic seizures: diminishes rapid muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: increased tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: mild stomach upset. - Coordination problems: difficulty with fine motor tasks.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Blood disorders: rare cases of neutropenia or thrombocytopenia.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: adjust dose in patients with reduced kidney function. - Psychiatric history: monitor for mood changes or depressive symptoms. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy: evaluate risk‑benefit, as safety data are limited. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: may decrease levetiracetam plasma levels, reducing efficacy. - Phenobarbital: can lower levetiracetam concentrations, compromising seizure control.

Moderate Interactions (Monitor Closely): - Alcohol: combined use may enhance central nervous system depression. - Sedative antihistamines: may increase drowsiness. - Other antiepileptic drugs: monitor therapeutic response when used in polytherapy.